IL309036A - Line-1 inhibitors as cognitive enhancers - Google Patents
Line-1 inhibitors as cognitive enhancersInfo
- Publication number
- IL309036A IL309036A IL309036A IL30903623A IL309036A IL 309036 A IL309036 A IL 309036A IL 309036 A IL309036 A IL 309036A IL 30903623 A IL30903623 A IL 30903623A IL 309036 A IL309036 A IL 309036A
- Authority
- IL
- Israel
- Prior art keywords
- inhibitors
- line
- cognitive enhancers
- cognitive
- enhancers
- Prior art date
Links
- 239000002475 cognitive enhancer Substances 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163197015P | 2021-06-04 | 2021-06-04 | |
| PCT/US2022/032120 WO2022256625A1 (en) | 2021-06-04 | 2022-06-03 | Line-1 inhibitors as cognitive enhancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL309036A true IL309036A (en) | 2024-02-01 |
Family
ID=84323626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL309036A IL309036A (en) | 2021-06-04 | 2022-06-03 | Line-1 inhibitors as cognitive enhancers |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240285664A1 (https=) |
| EP (1) | EP4346835A4 (https=) |
| JP (1) | JP2024520132A (https=) |
| KR (1) | KR20240017910A (https=) |
| CN (1) | CN117813096A (https=) |
| AU (1) | AU2022283915A1 (https=) |
| CA (1) | CA3221190A1 (https=) |
| IL (1) | IL309036A (https=) |
| MX (1) | MX2023014381A (https=) |
| WO (1) | WO2022256625A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250170158A1 (en) * | 2022-02-22 | 2025-05-29 | Rome Therapeutics, Inc. | Methods of treating medical conditions using censavudine or a related compound |
| WO2023178128A1 (en) * | 2022-03-15 | 2023-09-21 | Rome Therapeutics, Inc. | Methods of treating medical conditions using islatravir or a related compound |
| WO2024107850A1 (en) * | 2022-11-15 | 2024-05-23 | Rome Therapeutics, Inc. | Halo-dehydro-3'-deoxyuracil phosphoramidates and related compounds and their use in treating medical conditions |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3302454T (pt) * | 2015-05-26 | 2021-04-01 | Technophage Investig E Desenvolvimento Em Biotecnologia Sa | Composições para utilização no tratamento da doença de parkinson e distúrbios associados |
| EP3914604B1 (en) * | 2019-01-25 | 2026-03-04 | Brown University | Compositions comprising censavudine or elvucitabine for treating age-associated inflammation and disorders |
| KR20230107543A (ko) * | 2020-09-23 | 2023-07-17 | 트랜스포손 테라퓨틱스, 인코포레이티드 | 질병을 치료하기 위한 line-1 억제제 |
-
2022
- 2022-06-03 KR KR1020247000214A patent/KR20240017910A/ko active Pending
- 2022-06-03 CN CN202280048917.1A patent/CN117813096A/zh active Pending
- 2022-06-03 AU AU2022283915A patent/AU2022283915A1/en active Pending
- 2022-06-03 MX MX2023014381A patent/MX2023014381A/es unknown
- 2022-06-03 CA CA3221190A patent/CA3221190A1/en active Pending
- 2022-06-03 US US18/566,413 patent/US20240285664A1/en active Pending
- 2022-06-03 WO PCT/US2022/032120 patent/WO2022256625A1/en not_active Ceased
- 2022-06-03 JP JP2023574354A patent/JP2024520132A/ja active Pending
- 2022-06-03 EP EP22816917.3A patent/EP4346835A4/en active Pending
- 2022-06-03 IL IL309036A patent/IL309036A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023014381A (es) | 2023-12-15 |
| CN117813096A (zh) | 2024-04-02 |
| EP4346835A4 (en) | 2025-04-16 |
| KR20240017910A (ko) | 2024-02-08 |
| EP4346835A1 (en) | 2024-04-10 |
| WO2022256625A1 (en) | 2022-12-08 |
| AU2022283915A1 (en) | 2024-01-18 |
| US20240285664A1 (en) | 2024-08-29 |
| JP2024520132A (ja) | 2024-05-21 |
| CA3221190A1 (en) | 2022-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4262803A4 (en) | Tetrahydropyridopyrimidine pan-kras inhibitors | |
| EP4216951A4 (en) | KRAS G12D INHIBITORS | |
| EP4197538A4 (en) | Egfr inhibitor | |
| EP4083038A4 (en) | PYRIDAZINYL THIAZOLECARBOXAMIDE COMPOUND | |
| EP4434979A4 (en) | KIF18A INHIBITOR | |
| IL309036A (en) | Line-1 inhibitors as cognitive enhancers | |
| EP4137404A4 (en) | Multicopter | |
| EP4107782A4 (en) | MICROARRAYS | |
| KR20240099193A9 (ko) | Erbb 억제제로서의 다형체 | |
| EP4247372A4 (en) | PLASMA KALLICREIN INHIBITORS | |
| EP4168398A4 (en) | TYK-2 INHIBITOR | |
| EP4512238A4 (en) | TRANSPORT DEVICE | |
| EP4440587A4 (en) | MICROBIAL CONSORTIUMS | |
| EP4628384A4 (en) | SPONSORS | |
| EP4226919A4 (en) | FERROPTOSIS INHIBITOR | |
| EP4210694A4 (en) | PLASMA KALLICREIN INHIBITORS | |
| EP4643828A4 (en) | Conveyor | |
| IL315728A (en) | Targeted delivery | |
| CL2023000728A1 (es) | Compuestos y composiciones como inhibidores de sppl2a. | |
| EP3920340C0 (de) | Betätigungsclip | |
| EP4137402A4 (en) | MULTICOPTER | |
| EP4448515A4 (en) | PLPRO INHIBITORS | |
| EP4377295C0 (en) | HALOACETHYDRAZIDES USEFUL AS EPA INHIBITORS | |
| EP4178620A4 (en) | PLASMA KALLICREIN INHIBITORS | |
| HK40102937A (en) | Line-1 inhibitors as cognitive enhancers |